That may be one reason why the ability to monitor glucose levels on an Apple Watch became a favorite feature among Dexcom G5 users after its debut in 2015, and since then, many more users have ...

Shares of DexCom Inc. DXCM slipped 1.72% to $66.14 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.81% to 5,363.36 and ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems. Valued at $26.2 billion by ...

Video berdurasi 32 saat itu menunjukkan pekerja-pekerja tekstil di AS yang kelihatan muram, keletihan dan bekerja dalam suasana suram di kilang pakaian. Mereka kelihatan bertubuh besar, menjahit ...

Dexcom has a well-established record of introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, Dexcom has captured an impressive slice ...

Investing.com -- Shares of DexCom , Inc. (NASDAQ: DXCM) climbed 9% after the company announced that its Dexcom (NASDAQ:DXCM) G7 15 Day Continuous Glucose Monitoring (CGM) System received FDA clearance ...

The Food and Drug Administration (FDA) has cleared diabetes-management firm DexCom's (DXCM) new continuous glucose monitoring (CGM) system. The San Diego, Calif.-based firm said Thursday that its ...

FDA clears Dexcom G7 15-Day CGM for adults, offering 15.5 days of wear and a MARD of 8.0% for improved diabetes management. New features include Apple Watch connectivity, medication logging ...

DexCom shares rose in premarket trading Thursday morning after the company said it received regulatory clearance in the U.S. for its diabetes monitoring system. Shares traded 8.5% higher at $72.55 ...

Dexcom received Food and Drug Administration clearance for a 15-day version of its G7 glucose sensor, the company announced Thursday. Dexcom claims its continuous glucose monitor is the most ...

Investing.com -- Shares of DexCom , Inc. (NASDAQ: DXCM) climbed 9% after the company announced that its Dexcom (NASDAQ:DXCM) G7 15 Day Continuous Glucose Monitoring (CGM) System received FDA ...